ACXP
Acurx Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Acurx Pharmaceuticals, Inc.
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Acurx Pharmaceuticals, Inc.
1.05
−0.02 · −2.02%
−22.54%
shares held · 10 largest managers
No changes.
No changes.
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $48,203 | 25.99% | 0.00% |
| Geodeindex-like | $40,938 | 22.07% | +6.41% |
| Vanguard Fiduciary Trustindex-like | $25,118 | 13.54% | 0.00% |
| Jane Street | $24,377 | 13.14% | −71.22% |
| Prospect Financial Services | $21,367 | 11.52% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $48,203 | 25.99% | 0.00% |
| Geodeindex-like | $40,938 | 22.07% | +6.41% |
| Vanguard Fiduciary Trustindex-like | $25,118 | 13.54% | 0.00% |
| Jane Street | $24,377 | 13.14% | −71.22% |
| Prospect Financial Services | $21,367 | 11.52% | 0.00% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Acurx Pharmaceuticals, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Acurx Pharmaceuticals, Inc..
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.